Source:http://linkedlifedata.com/resource/pubmed/id/20195673
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2010-3-18
|
| pubmed:abstractText |
Patients with fever and granulocytopenia are at risk of developing severe infection. We performed a prospective, randomized trial to evaluate the efficacy of low-dose cefepime plus amikacin (C-A) compared to low-dose piperacillin/tazobactam plus amikacin (PT-A). Patients received cefepime (2 g/12 h) plus amikacin (15 mg/kg/day) or piperacillin/tazobactam (4 g/500 mg/8 h) plus amikacin. A total of 317 episodes of febrile granulocytopenia in 190 patients were studied (152 in the C-A group, 165 in the PT-A group). A microbiologically documented infection was present in 53 (35%) episodes in the C-A group and 41 (25%) episodes in the PT-A group (p = ns); a clinically documented infection was observed in 39 (26%) and 47 (28%) episodes, respectively. Toxicity was observed in 6 (4%) episodes in the C-A group and in 5 (3%) episodes in the PT-A group. The antibiotic success rate (no change or addition of antibiotics) was recorded in 89 (59%) and 105 (64%) cases, respectively (p = ns). Mortality related to infection was similar in each arm (3.9% vs. 3.6%). Combination therapy of low-dose beta-lactam with an aminoglycoside achieves very good response rates and low rates of toxicity. It might be an attractive option in an environment of increasing resistance among gram-negative bacteria.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amikacin,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cephalosporins,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillanic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Piperacillin,
http://linkedlifedata.com/resource/pubmed/chemical/cefepime,
http://linkedlifedata.com/resource/pubmed/chemical/piperacillin-tazobactam...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1435-4373
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
29
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
417-27
|
| pubmed:meshHeading |
pubmed-meshheading:20195673-Adolescent,
pubmed-meshheading:20195673-Adult,
pubmed-meshheading:20195673-Aged,
pubmed-meshheading:20195673-Aged, 80 and over,
pubmed-meshheading:20195673-Amikacin,
pubmed-meshheading:20195673-Anti-Bacterial Agents,
pubmed-meshheading:20195673-Cephalosporins,
pubmed-meshheading:20195673-Female,
pubmed-meshheading:20195673-Fever of Unknown Origin,
pubmed-meshheading:20195673-Humans,
pubmed-meshheading:20195673-Incidence,
pubmed-meshheading:20195673-Male,
pubmed-meshheading:20195673-Middle Aged,
pubmed-meshheading:20195673-Neutropenia,
pubmed-meshheading:20195673-Penicillanic Acid,
pubmed-meshheading:20195673-Piperacillin,
pubmed-meshheading:20195673-Poisoning,
pubmed-meshheading:20195673-Prospective Studies,
pubmed-meshheading:20195673-Treatment Outcome,
pubmed-meshheading:20195673-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.
|
| pubmed:affiliation |
Infectious Diseases Unit, Hospital Universitari Mutua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain. lgomez@mutuaterrassa.es
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial
|